Profile
Robert J.
Stagg worked as a Medical Monitor at Genentech, Inc. from 1991 to 1993.
He then worked as the Director of Clinical Research at Gilead Sciences, Inc. from 1993 to 1996.
From 1996 to 2001, he worked as the Vice President of Clinical Research at Coulter Pharmaceuticals, Inc. He then worked as the Senior Director of Clinical Research at Tularik, Inc. from 2001 to 2003.
From 2003 to 2006, he worked as the Vice President of Regulatory Affairs & Safety at Protein Design Labs, Inc. He also worked as an Assistant Clinical Professor at The University of California, San Francisco from 1983 to 1991.
He was the Senior VP of Clinical Research and Development at OncoMed Pharmaceuticals, Inc. from 2016 to 2019.
He holds a doctorate degree from the University of the Pacific.
Former positions of Robert J. Stagg
Companies | Position | End |
---|---|---|
ONCOMED PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | - |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | General Counsel | 2006-01-09 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 2003-04-30 |
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Chief Tech/Sci/R&D Officer | 2000-12-31 |
GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 1996-11-30 |
Training of Robert J. Stagg
University of the Pacific | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
Private companies | 6 |
---|---|
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Stock Market
- Insiders
- Robert J. Stagg